GlassScriptPhysician profile
Samina Reza
NPI 1457460479
$9,172.41
in general payments reported to CMS, 2019-2025
60 companies · $848 in 2025
The $848 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,691 · 2020: $1,289 · 2021: $779 · 2022: $2,032 · 2023: $1,714 · 2024: $819 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,261 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,260.88 |
| Education | $120.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,223.33 | 2019-2025 | |
| Pfizer INC. | $1,011.82 | 2019-2025 | |
| Eisai INC. | $875.90 | 2019-2025 | |
| Lilly USA, LLC | $875.61 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $423.44 | 2019-2023 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $389.01 | 2019-2023 | |
| Incyte Corporation | $327.18 | 2019-2025 | Jakafi |
| Janssen Biotech, INC. | $302.10 | 2019-2022 | |
| Gilead Sciences, INC. | $301.63 | 2019-2024 | Trodelvy |
| Astellas Pharma US INC | $301.47 | 2019-2024 | Padcev |
| Astrazeneca Pharmaceuticals LP | $291.48 | 2019-2023 | Calquence |
| Regeneron Healthcare Solutions, INC. | $261.80 | 2022-2025 | Libtayo |
| Genzyme Corporation | $191.64 | 2021-2025 | |
| Amgen INC. | $189.60 | 2019-2022 | |
| Kite Pharma, INC. | $140.89 | 2019-2020 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samina Reza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.